Individuals with SNCA pathogenic variants reported painful dystonia, lower extremity pain, dorsal pain, and upper back pain, though observations are primarily based on case reports with unclear preval

Genetic_Association Score: 0.500 Price: $0.50 Parkinson's disease human Status: extracted

What This Experiment Tests

Genetic_Association experiment designed to assess clinical efficacy targeting SNCA in human. Primary outcome: Individuals with SNCA pathogenic variants reported painful dystonia, lower extremity pain, dorsal pa

Description

Systematic review of 63 articles; findings based on case reports and heterogeneous study designs

TARGET GENE

SNCA (Score: 0.605)

MODEL SYSTEM

human

ESTIMATED COST

TIMELINE

0 months

PATHWAY

null

SOURCE

pmid_38020640

PRIMARY OUTCOME

Individuals with SNCA pathogenic variants reported painful dystonia, lower extremity pain, dorsal pain, and upper back pain, though observations are primarily based on case reports with unclear prevalence.

Scoring Dimensions

Related Hypotheses (6)

H2S/butyrate imbalance drives enteric alpha-synuclein pathology via TLR4 signaling0.380

Exosomal SNCA Propagation from Lysosome-Compromised Neurons Contains a Distinct Lysosomal Proteome S0.777

SNCA Aggregation Hijacks the Endosomal Sorting Complex Required for Transport (ESCRT) Machinery via 0.690

m6A Hypermethylation of SNCA mRNA Stabilises Alpha-Synuclein Transcript and Promotes Lewy Pathology0.662

Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-first or ENS-first mec0.650

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.